GB Sciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GBLX research report →
Price Chart
About the company
Operating across North America and Europe, GB Sciences, Inc. is dedicated to the research and development of plant-based pharmaceuticals. The company specializes in crafting cannabinoid-inspired medications and complex therapeutic formulations intended for the prescription drug market.
- CEO
- Andrea Small-Howard
- IPO
- 2008
- Employees
- 2
- HQ
- Las Vegas, NV, US
Get TickerSpark's AI analysis on GBLX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $122.12K
- P/E
- -0.07
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.02
- EV/EBITDA
- -1.32
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 28.02%
- ROIC
- 39.97%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-624+99.0%
- Op Income
- $-1,421,000
- Net Income
- $-1,362,000+67.0%
- EPS
- $-0.00+64.3%
- OCF Growth
- +36.1%
- FCF Growth
- +37.4%
- 52W High
- $0.50
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 9.86
- RSI (14)
- 48
- Avg Volume
- 51.57K
No earnings-call transcripts are available for GBLX yet.
- Free Float
- 98.7%
- Shares Outstanding
- 407.07M
- Float Shares
- 401.85M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 11, 18 | POSS JOHN C | buy | 3,615 |
| Jul 11, 18 | POSS JOHN C | buy | 11,915 |
| Jul 11, 18 | POSS JOHN C | buy | 20,000 |
| Jul 11, 18 | POSS JOHN C | buy | 1,250 |
| Jul 11, 18 | POSS JOHN C | buy | 30,000 |
| Jul 11, 18 | POSS JOHN C | buy | 23,184 |
| Jul 11, 18 | POSS JOHN C | buy | 10,000 |
| Aug 10, 15 | POSS JOHN C | other | 0 |
| Nov 27, 17 | POSS JOHN C | other | 937,500 |
| Jun 1, 16 | POSS JOHN C | other | 1,400,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GBLX coverage
Recent articles, reports, and earnings notes.
No research on GBLX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GBLX report →GB Sciences (OTCMKTS:GBLX) Stock Passes Above 50 Day Moving Average – What’s Next?
defenseworld.net · Jan 21
Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation
globenewswire.com · Sep 14
Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference
globenewswire.com · Sep 9
GB Sciences Is Developing Plant-Inspired Mixtures for Anxiety, Depression, and Pain From PhAROS, GB Sciences' Proprietary AI-Accelerated Drug Discovery Platform
accesswire.com · Jul 27
GB Sciences Using AI Technology in Plant-Based Drug Discovery Research
accesswire.com · Jun 29
GB Sciences' Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President
accesswire.com · Jun 17
GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals
accesswire.com · Apr 20
GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform
accesswire.com · Apr 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.